- Wednesday, November 18, 2026

With the withdrawal of Heidi Overton’s nomination leaving the FDA without a permanent commissioner for the foreseeable future, America’s physicians and pharmacists are urging the Department of Health and Human Services (HHS) to rescind a federal policy that is already exposing patients to unapproved, inadequately studied injectable drugs. HHS should listen before another preventable tragedy occurs.

On Oct. 28, HHS announced that it would refrain from enforcement against qualifying pharmacies and physicians compounding six experimental peptides, over the objections of the Food and Drug Administration’s own scientific reviewers.

FDA’s Center for Drug Evaluation and Research recommended against adding these six substances to the list of ingredients eligible for traditional pharmacy compounding. Yet an advisory committee nevertheless supported their inclusion, with eight newly appointed members with financial ties to the peptide industry providing decisive votes. HHS then advanced this policy while FDA was operating without a Senate-confirmed commissioner.

People were interested in these podcasts

Now some of the nation’s most prominent medical and pharmacy organizations are calling for the policy to be reversed.

On Nov. 9, the American Medical Association (AMA) formally urged HHS to immediately rescind its decision to ease restrictions on unapproved peptides and pursue enforcement against illegal distributors. The American Pharmacists Association (APhA) likewise called for withdrawal, warning that enforcement discretion cannot substitute for scientific review and established patient-safety protections. The American Society of Health-System Pharmacists (ASHP) also criticized HHS’s reliance on enforcement discretion rather than established rulemaking, citing limited clinical and safety data.

As former presidents of APhA and ASHP, we share these concerns. Through the Alliance for Safe Biologic Medicines, we have repeatedly raised them with HHS Secretary Robert F. Kennedy, Jr., most recently in our Nov. 13 formal comments urging withdrawal of the policy.

The safeguards at issue exist for good reason. In 2012, contaminated steroid injections produced by the New England Compounding Center caused a nationwide fungal meningitis outbreak. More than 100 patients died and more than 800 were sickened. The tragedy prompted Congress to strengthen oversight through the Drug Quality and Security Act. We should not need another catastrophe to remember why.

Yet disturbing evidence continues to emerge about illegally compounded drugs. The FDA received two reports of deaths following use of products purportedly containing retatrutide, an experimental weight-loss peptide. FDA has also received more than 1,700 adverse-event reports associated with compounded semaglutide and tirzepatide. Following a December 2025 FDA warning letter citing serious deficiencies in its sterile drug production practices that put patients at risk, another compounding pharmacy recalled compounded tirzepatide injections nationwide in September 2026 over sterility concerns.

The risks extend beyond American pharmacies to the overseas manufacturers supplying their active pharmaceutical ingredients (APIs). FDA found evidence of noncompliance at 21% of the 48 GLP-1 foreign API manufacturing sites it evaluated. In May, the agency documented serious violations at China’s Harbin Jixianglong Biotech, including relabeling ingredients from unapproved suppliers and inadequate testing for impurities and bacterial endotoxins. The company subsequently recalled two batches of semaglutide ingredients.

Similarly, in November Health Canada reported bacterial contamination in unauthorized injectable peptides supplied by a Chinese manufacturer. Authorities seized more than 11,400 vials, and two Canadian retail websites ceased operating following enforcement actions. Another investigation uncovered contaminated injectable peptides sold by an Ottawa wellness business.

In announcing it policy, HHS cited “significant interest” in compounded peptides, while Sec. Kennedy’s policy asserted that expanding access would advance “patient choice and freedom.” But public interest in a therapy cannot determine its safety and efficacy, its appropriate dosing, and its potential adverse effects.

HHS should heed its scientific experts and the medical and pharmacy professions and withdraw its policy until it can demonstrate adequate clinical evidence, independent scientific review, reliable ingredient traceability, effective adverse-event reporting and meaningful enforcement against illegal suppliers.

• Ronald P. Jordan, RPh, FAPhA, is the founding and emeritus dean of Chapman University School of Pharmacy and a past president of the American Pharmacists Association. Philip J. Schneider, MS, FASHP, FFIP, is a professor at The Ohio State University College of Pharmacy and a past president of the American Society of Health-System Pharmacists. Both serve on the Advisory Board of the Alliance for Safe Biologic Medicines. Learn more at www.SafeRxCompounding.org

Copyright © 2026 The Washington Times, LLC. Click here for reprint permission.

Please read our comment policy before commenting.